Interpharma Investments Limited appoints multidisciplinary healthcare leader Christiane Hamacher as new board director

Interpharma Investments Limited (IIL), the holding company of leading healthcare solutions provider Zuellig Pharma, today announced the appointment of Dr. Christiane Hamacher as a new member of its Board of Directors, effective 20 August 2024.

Dr. Hamacher joins Interpharma Investments Limited with over two decades of experience in the pharmaceutical and biotech industries, having served in numerous executive and non-executive appointments. She has worked closely with Boards and management teams of various industry-leading organisations on issues related to developing future-oriented business models, global strategic portfolio planning and organisation transformation.

She currently serves as a member of the Supervisory Board of Xencura, a German biodigital pharma platform company. Dr. Hamacher also has extensive experience serving in leadership roles across the value chain, including positions in commercial, operations, HR and lifecycle management functions. She was most recently Chief Executive Officer of Biocon Biologics, following her role as Head of Asia Pacific at Roche and various executive roles at Schering AG.

The IIL Board would like to take this opportunity to welcome Dr. Hamacher, and we look forward to working closely with her to achieve greater successes for Zuellig Pharma.